PARIS--(BUSINESS WIRE)--Regulatory News: “(CAP), is developed in a consortium associating the academic research, industrials and melanoma clinicians, with notably a research extended to specific “companion” BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), a company dedicated to specialty and orphan oncology products, today announced preliminary phase I clinical results with its AMEP® biotherapy developed in advanced or metastatic melanoma, an invasive skin cancer of bad prognosis.
